Sun, Feb 1, 2015, 12:16 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MELA Sciences, Inc. Message Board

  • rodentologist@bellsouth.net rodentologist Jul 20, 2013 6:14 PM Flag

    NY Times Article Indicates MelaFind Might be Useless

    Excerpt from NY Times:

    For decades, dermatologists have used their eyes, along with a magnifier called a dermatoscope, to try to distinguish abnormal but benign lesions from potential melanoma in order to avoid unneeded biopsies. Some dermatologists argue that these low-tech tools are still the most useful and worry that their colleagues are falling for expensive, cool-looking gadgets that may simply offer extraneous, and perhaps incorrect, data.

    “This technology should still be considered to be in the developmental stage,” said Dr. Roberta Lucas, an instructor of clinical dermatology at the Northwestern University Feinberg School of Medicine in Chicago. “We are better off when the system supports doctors who are thorough and unhurried; who examine and listen carefully and who empower patients to practice good surveillance and sun protection.”

    In fact, some members of an expert medical panel asked to review MelaFind a few years ago for the Food and Drug Administration warned that the device had the potential to give doctors and patients a false sense of security. While MelaFind can analyze small pigmented spots identified by dermatologists as having signs of melanoma, it is not designed to evaluate other problems: large melanomas, colorless melanomas or two other types of skin cancer — basal and squamous cell carcinoma.

    Dr. Amy E. Newburger, a dermatologist in Scarsdale, N.Y., who was a member of that F.D.A. panel, told me that she was concerned that a doctor could inadvertently use MelaFind on a non-melanoma skin cancer, receive a score indicating that the spot was not irregular, and erroneously decide not to biopsy it. She voted against recommending the device for F.D.A. approval.

    Some biostatisticians are also critical of MelaFind, saying the device can recognize a high percentage of melanomas correctly because it also falsely scores as positive so many non-melanomas — potentially prompting doctors to perform unnecessary biopsies.

    continued

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Some biostatisticians are also critical of MelaFind, saying the device can recognize a high percentage of melanomas correctly because it also falsely scores as positive so many non-melanomas — potentially prompting doctors to perform unnecessary biopsies."

      It is worth noting that MELA realizes the problems with marketing the MELAFind as a melanoma scoring device, and has announced that it is " transitioning MelaFind® from a melanoma scoring technology to a dermal imaging and metrics clinical tool"

      LOL. It's no longer a melanoma predictor - it's takes pictures and measurements.

      • 1 Reply to centralscrutinizzer
      • "Some biostatisticians are also critical of MelaFind, saying the device can recognize a high percentage of melanomas correctly because it also falsely scores as positive so many non-melanomas — potentially prompting doctors to perform unnecessary biopsies."

        LMAO!
        Old news hack. Your hero keeps bringing this up. The Cleveland Clinic independent report has put this to rest.

    • "Some biostatisticians are also critical of MelaFind, saying the device can recognize a high percentage of melanomas correctly because it also falsely scores as positive so many non-melanomas — potentially prompting doctors to perform unnecessary biopsies."

      "In the study, an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. Following the MelaFind data, 64 of those lesions were identified for biopsy and 102 were selected for continued observation. The report stated, "The results showed 61% of the clinically suspicious pigmented lesions in an at-risk population were deferred from biopsy, indicating that MelaFind analysis may prevent overly aggressive biopsy decisions. There may also be an overall improvement in biopsy risk." The study was conducted independently and not sponsored by MELA Sciences, Inc." 2013 Outcomes for Cleveland Clinic's Dermatology & Plastic Surgery Institute

      • 3 Replies to b767cpt1
      • rodentologist@bellsouth.net rodentologist Oct 24, 2014 10:01 AM Flag

        In conclusion, the MelaToy

        1) Did not find a single cancer not found by the dermatoscope.

        2) Caused biopsies that turned out to be unnecessary, biopsies derms using the dermatoscope would not have done.

        And somehow this is supposed to show the stupid toy is *good*??????

      • rodentologist@bellsouth.net rodentologist Oct 24, 2014 9:59 AM Flag

        And the situation is even WORSE for mela. Not only did it not catch a sungle melanoma that was not caught by the dermatologists, but it caused needless biopsies. While it did not biopsy all the lesions the derms were not concerned about, it biopsied *some*. But none of these had cancers!!!

        In other words, around 100 lesions were not considered serious by the derms. The MelaToy had around 40 biopsied, and 60 not. Those 40 were NOT cancerous. So somehow the idiots at the Cleveland Clinic concluded that because it did not lead to 100 wasted biopsies, but rather only 40 wasted biopsies, it was preventing wasted biopsies. It is like a serial killer who kills 10 people rather than 12 arguing that he is beneficial because he saved 2 people from being killed who he otherwise could have killed.

      • rodentologist@bellsouth.net rodentologist Oct 24, 2014 9:54 AM Flag

        Cognitively impaired parcel boy just repeats the hype, completely ignoring the actual question, like the monkey he is.

        Here is the question again:

        Did the dermatologists NOT using the MelaToy miss even a SINGLE case of melanoma? Do not mindlessly copy-and-paste. Answer either "yes" or "no".

        When you studied parcel math at UPS training school, and you were asked "If you are given 100 parcels and have delivered 100 of them, do you have any parcels left?" did you have trouble with the fact that it was a yes/no question?

        Here is the question yet again, you complete fugging idiot. Did the dermatologists NOT using the MelaToy miss even a SINGLE melanoma. Answer "yes" or "no".

    • You seem have no life beside bashing this stock....what an idiot
      Go get girlfriend or a boy if you're gay...

    • lololololoololol

      too funny. i give you the info you requested, and you're still trying to compare melafind to a magnifying glass with a flashlight lolololololololololol

      i can bring someone to the water but i cant force them to drink.

      good luck.

    • NYT very negative.

 
MELA
1.38-0.0100(-0.72%)Jan 30 3:28 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.